Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

1.030 +0.050 (+5.10%)

Delayed Quote Updated: 12:38 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Telomir Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases

August 28, 2025

Via ACCESS Newswire

Stock Market Today: Nvidia Drags Down Nasdaq Futures—Dollar General, Dell, Best Buy In Focus ↗

August 28, 2025

U.S. stock futures were swinging on Thursday following Wednesday's advances. Futures of major benchmark indices were largely mixed.

Via Benzinga

Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗

August 28, 2025

Via Benzinga

Why Telomir Pharmaceuticals Stock Ran Up 35% On Wednesday Night ↗

August 28, 2025

Telomir Pharmaceuticals' shares jumped 35% after promising data showed its lead drug Telomir-1 may offer a safer, dual-action treatment for cancer and aging-related diseases.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 27, 2025

Via Benzinga

Wednesday's after hours session: top gainers and losers ↗

August 27, 2025

Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

August 07, 2025

Via ACCESS Newswire

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in

July 24, 2025

Via ACCESS Newswire

Get insights into the top gainers and losers of Monday's pre-market session. ↗

July 21, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 21, 2025

Via Benzinga

Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket ↗

July 21, 2025

Via Benzinga

Top stock movements in today's session. ↗

July 18, 2025

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

Most active stocks in Friday's session ↗

July 18, 2025

Discover the most active stocks in Friday's session. Stay informed about the stocks that are generating the most trading volume!

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 18, 2025

Via Benzinga

Dow Falls Over 200 Points; 3M Earnings Top Views ↗

July 18, 2025

Via Benzinga

Topics Stocks

On Friday, there are stocks with unusual volume. Let's take a look. ↗

July 18, 2025

On Friday, there are stocks with unusual volume. Let's take a look.

Via Chartmill

Friday's session: top gainers and losers ↗

July 18, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Gapping stocks in Friday's session ↗

July 18, 2025

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

US Stocks Mixed; American Express Posts Upbeat Q2 Results ↗

July 18, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 18, 2025

Via Benzinga

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

July 18, 2025

Via ACCESS Newswire

Why Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗

July 18, 2025

Via Benzinga

US Stocks Likely To Open Higher After Scaling Record Close: American Express, 3M, Charles Schwab Earnings In Focus ↗

July 18, 2025

U.S. stock futures were positive on Friday after ending higher on Thursday. Futures of major benchmark indices were higher.

Via Benzinga

Telomir Pharma Skyrockets Nearly 139% After-Hours As Cancer Drug Shows Breakthrough Results, Beats Chemo In Human Cell Tests ↗

July 18, 2025

Following the announcement of promising data regarding Telomir-1, Telomir Pharmaceuticals Inc stock surged 138.84% during after-hours trading on Thursday,

Via Benzinga

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains ↗

July 17, 2025

The early lab study used cells from a child with progeria and showed improvements in cell survival, reduced oxidative stress, and restored mitochondrial function, which are key signs of aging.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 17, 2025

Via Benzinga

Which stocks are moving after the closing bell on Thursday? ↗

July 17, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 30, 2025

Via Benzinga

BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success for Telomir-1 in Progeria Cell Lines

June 18, 2025

Via Investor Brand Network

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

June 18, 2025

Via ACCESS Newswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.